The role of MEKK1 in hypertrophic cardiomyopathy

International Heart Journal

Volumn 51, Issue 4, 2010, Pages 277-284

  Konhilas, John P ^a   Boucek, Dana M ^a   Horn, Todd R ^a   Johnson, Gary L ^b   Leinwand, Leslie A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase 3; Hypertrophic cardiomyopathy; Matrix metalloproteinase; Urokinase type plasminogen activator; Ventricular remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CASPASE 3; CASPASE 9; CYTOCHROME C; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MUTANT PROTEIN; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PROTEIN BCL 2; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR JUNB; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CARDIOMEGALY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; GENE DELETION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HYPERTROPHIC CARDIOMYOPATHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; MALE; MAP KINASE KINASE KINASE 1; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOSIN HEAVY CHAINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77955782565     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.277     Document Type: Article

References (39)

1. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11: 211-218. (Review)
2. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 1993; 260: 315-319.
3. Yujiri T, Sather S, Fanger GR, Johnson GL. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 1998; 282: 1911-1914.
4. Nadal-Ginard B, Mahdavi V. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989; 84: 1693-1700. (Review)
5. Minamino T, Yujiri T, Terada N, et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci U S A 2002; 99: 3866-3871.
6. Dorn GW 2nd, Brown JH. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med 1999; 9: 26-34. (Review)
7. Karin M. The regulation of ap-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci 1996; 351: 127-134. (Review)
8. De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 1995; 11: 365-376.
9. Witowsky J, Abell A, Johnson NL, Johnson GL, Cuevas BD. MEKK1 is required for inducible urokinase-type plasminogen activator expression. J Biol Chem 2003; 278: 5941-5946.
10. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5: 1135-1142.
11. D'Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 1997; 94: 8121-8126.
12. Sadoshima J, Montagne O, Wang Q, et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 2002; 110: 271-279.
13. Vikstrom KL, Factor SM, Leinwand LA. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol Med 1996; 2: 556-567.
14. Konhilas JP, Watson PA, Maass A, et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 2006; 98: 540-58.
15. Stauffer BL, Konhilas JP, Luczak ED, Leinwand LA. Soy diet worsens heart disease in mice. J Clin Invest 2006; 116: 209-216.
16. Yujiri T, Ware M, Widmann C, et al. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation. Proc Natl Acad Sci U S A 2000; 97: 7272-7277.
17. Olsson MC, Palmer BM, Stauffer BL, Leinwand LA, Moore RL. Morphological and functional alterations in ventricular myocytes from male transgenic mice with hypertrophic cardiomyopathy. Circ Res 2004; 94: 201-207.
18. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102: 1944-1949.
19. Konhilas JP, Maass AH, Luckey SW, Stauffer BL, Olson EN, Leinwand LA. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol 2004: 287; H2768-H2776.
20. Mercadier JJ, Lomprè AM, Wisnewsky C, et al. Myosin isoenzyme changes in several models of rat cardiac hypertrophy. Circ Res 1981; 49: 525-532.
21. Luckey SW, Mansoori J, Fair K, Antos CL, Olson EN, Leinwand LA. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males. Am J Physiol Heart Circ Physiol 2007; 292: H838-H845.
22. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene. 2006; 25: 4998-5010.
23. Cuevas BD, Uhlik MT, Garrington TP, Johnson GL. MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability. Oncogene 2005; 24: 801-809.
24. Heymans S, Schroen B, Vermeersch P, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136-1144.
25. Olsson MC, Palmer BM, Leinwand LA, Moore RL. Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2001; 280: H1136-H1144.
26. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316. (Review)
27. Molkentin JD, Dorn GW 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63: 391-426. (Review)
28. Hilfiker-Kleiner D, Hilfiker A, Castellazzi M, et al. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovasc Res 2006; 71: 108-117.
29. Pollack PS, Pasquarello LM, Budjak R, et al. Differential expression of c-jun and junD in end-stage human cardiomyopathy. J Cell Biochem 1997; 65: 245-253.
30. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004; 68: 355-360.
31. Fedak PW, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 2003; 284: H626-H634.
32. Fedak PW, Smookler DS, Kassiri Z, et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 2004; 110: 2401-2409.
33. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
34. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Review)
35. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95: 3C-8C. (Review)
36. Di Girolamo N, Indoh I, Jackson N, et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol 2006; 177: 2638-26350.
37. Watson PA, Reusch JE, McCune SA, et al. Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise. Am J Physiol Heart Circ Physiol 2007; 293: H246-H259.
38. Nawata R, Yujiri T, Nakamura Y, et al. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappa B activation. Oncogene 2003; 22: 7774-7780.
39. Braz JC, Bueno OF, Liang Q, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 2003; 111: 1475-1486.